Method of Administering Porcine B-domainless fVIII

A pharmaceutical composition for administration to a patient having factor VIII deficiency to achieve and maintain a therapeutically effective level of factor VIII in said patient, wherein the composition comprises OBI-1 at a concentration from 50 to 10,000 Units/mL and a physiologically acceptable carrier, wherein the OBI-1 is a product of expression of a nucleic acid molecule encoding SEQ ID NO:2.

A method of reducing blood clotting time in a patient having factor VIII deficiency, comprising administering a composition comprising a porcine partially B-domainless factor VIII (OBI-1) and a physiologically acceptable carrier to the patient in need thereof in an amount sufficient to reduce the patient's blood clotting time to a desired value wherein the amount of OBI-1 sufficient to reduce the patient's blood clotting time is ½ to 1/10 of the amount of plasma-derived porcine factor VIII sufficient to achieve the same reduction of blood clotting time obtained upon administering the partially B-domainless porcine fVIII (OBI-1), and wherein said OBI-1 is the expression product of SEQ ID NO:1, and wherein the OBI-1 is administered at a rate of 1000-10,000 Units/minute.

A method of administering a porcine partially B-domainless factor VIII (OBI-1) to a patient having factor VIII deficiency, said patient having factor VIII-inhibiting antibodies, wherein the porcine B-domainless factor VIII is administered intravenously to said patient in combination with a physiologically acceptable carrier at a dose about 10-150 Units/kg of body weight and at a rate of 1000-10,000 Units/minute, and wherein said OBI-1 is the expression product of DNA encoding SEQ ID NO:2.

A method of reducing blood clotting time in a patient having factor VIII deficiency, comprising administering a composition comprising a porcine partially B-domainless factor VIII (OBI-1) and a physiologically acceptable carrier to the patient in an amount sufficient to reduce the patient's blood clotting time wherein the amount of OBI-1 sufficient to reduce the patient's blood clotting time is ½ to 1/10 of the amount of plasma-derived porcine factor VIII sufficient to achieve the same reduction of blood clotting time obtained upon administering a B-domainless porcine fVIII (OBI-1), wherein said OBI-1 is administered at a rate of 1000-10,000 Units/minute and wherein said OBI-1 is the expression product of SEQ ID NO:1.

A method of administering a porcine B-domainless fVIII (OBI-1) to control a bleeding episode in a hemophilia A patient in need of such control comprising the steps of

• a) administering to the patient an intravenous dose of from 10-150 U/kg patient weight of OBI-1 without administration of an antibody-neutralizing dose of OBI-1 whereby bleeding is controlled, wherein said OBI-1 is the expression product of SEQ ID NO:1, wherein said OBI-1 is administered at a rate of 1000-10,000 Units/minute, or
• b) if bleeding is not controlled, giving subsequent doses as in step (a), at 4-12 hour intervals until bleeding is controlled.